A more nuanced review of this evidence can be found on page 10 in the 2014 iteration of the under section Populations Excluded from this Guideline. [13] Our updated systematic evidence review found no new evidence that would alter this position. Genetic dyslipidemia conditions (e.g., homozygous FH [HoFH], heterozygous FH [HeFH], TGs >500 mg/dL, etc.) were also excluded from the guideline given their uncommon occurrence and sparse clinical trial data. Although younger patients (i.e., <40 years old) are more common in the DoD, this cohort comprises a low short-term risk population that has been excluded from dyslipidemia intervention trials. Thus, the Work Group was unable to provide evidence-based recommendations for these populations and suggests that providers consider basing treatment decisions for these cohorts on comorbidity, quality of life, and patient s values and preferences. Such shared and informed decision making should clearly lay out the uncertainty of benefit and known risks associated with pharmacologic treatment. E. Patient-centered Care Guideline recommendations are intended to consider a patient s needs and preferences and be patient centered, culturally appropriate, and available to people with limited literacy skills, and physical, sensory, or learning disabilities. VA/DoD CPGs encourage providers to use a patient-centered approach (i.e., individualized treatment based on patient needs, characteristics, and preferences). Regardless of the setting, all patients should be able to access evidence-based care that is appropriate to them. Patient- centered care may decrease patient anxiety, increase trust in providers, and improve treatment adherence.[14-16] Good communication is essential and should be supported by evidence-based information tailored to the patient s needs. An empathetic and non-judgmental approach facilitates discussions sensitive to gender, culture, ethnicity, and other differences. 